E Fund CSI Innovative Drugs ETF (516080) Rises 1.31% in Early Trading; Multiple Pharmaceutical Companies Approach Profitability Inflection Point

NewTimeSpace News - As of 09:53 on March 27, 2026, the E Fund Innovative Medicine ETF (516080) rose 1.31%, with its latest price reaching 0.62 yuan. Looking at a longer timeframe, as of March 26, 2026, the ETF has accumulated a gain of 9.48% over the past year, ranking 1st among 7 comparable funds. (The stocks listed above are solely index constituents and do not constitute specific investment recommendations.)

In terms of liquidity, the E Fund Innovative Medicine ETF recorded an intraday turnover rate of 0.91% and a trading volume of 10.5997 million yuan. Looking at a longer timeframe, as of March 26, the ETF's average daily trading volume reached 27.7898 million yuan over the past week, ranking among the top 3 comparable funds.

Regarding fund size, the E Fund Innovative Medicine ETF has grown by 720 million yuan over the past year, representing a significant increase and ranking 3rd among 7 comparable funds in terms of new asset inflows. (Data source: Wind)

In terms of fund shares, the E Fund Innovative Medicine ETF increased by 22 million shares this month, achieving substantial growth and ranking 3rd among 7 comparable funds in terms of new share additions. (Data source: Wind)

For capital flows, the E Fund Innovative Medicine ETF recorded a net outflow of 618,700 yuan in the latest session. Looking at a longer timeframe, over the past 19 trading days, 11 days saw net inflows, with a total of 14.7485 million yuan attracted. (Data source: Wind)

Data indicates continued positioning by leveraged funds. The E Fund Innovative Medicine ETF recorded a margin purchase of 1.0899 million yuan in the latest session, with its latest margin balance reaching 21.8004 million yuan. (Data source: Wind)

As of March 26, the E Fund Innovative Medicine ETF has gained 14.99% over the past 2 years, ranking first among comparable funds. In terms of return capability, as of March 26, 2026, since its inception, the ETF has achieved a maximum monthly return of 22.96%, a maximum consecutive rising period of 5 months, a maximum consecutive gain of 33.43%, and an average monthly return of 5.75% during rising months. As of March 26, 2026, the E Fund Innovative Medicine ETF has outperformed its benchmark by 3.11% in annualized returns since inception.

Regarding drawdown, as of March 26, 2026, the E Fund Innovative Medicine ETF's relative benchmark drawdown this year was 0.03%, representing the smallest drawdown among comparable funds.

In terms of fee structure, the E Fund Innovative Medicine ETF charges a management fee of 0.15% and a custody fee of 0.05%, representing the lowest fee level among comparable funds.

For tracking accuracy, as of March 26, 2026, the E Fund Innovative Medicine ETF's tracking error over the past month was 0.009%.

From a valuation perspective, the CSI Innovative Medicine Industry Index tracked by the ETF currently has a price-to-earnings ratio (PE-TTM) of only 42.51x, standing at the 1.9th percentile over the past year, meaning the valuation is lower than 98.1% of the time during the past year, indicating a historically low level.

The E Fund Innovative Medicine ETF closely tracks the CSI Innovative Medicine Industry Index, which selects up to 50 most representative listed companies from among those whose main business involves innovative drug research and development as index constituents to reflect the overall performance of innovative medicine industry listed companies.

On the news front, multiple pharmaceutical companies are approaching profitability inflection points. Hengrui Medicine's 2025 annual report shows innovative drug revenue grew 26% year-on-year, accounting for nearly 60% of total revenue, with BD licensing revenue contributing over 3 billion yuan. InnoCare Pharma, Everest Medicines, and XtalPi Holdings all achieved year-on-year profitability turnaround in 2025, validating that the industry has entered a new phase transitioning from "burning cash on R&D" to "profit realization."

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.